[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

$rvmds

$RVMD social media engagement is up significantly over the past year, with a notable surge in interactions and a growing number of active creators discussing the project. This increased activity suggests a rising interest and potential for future development.

About $rvmds

$RVMD refers to the development and community surrounding a decentralized social media platform.

Engagements: XX (24h)

Engagements 24-Hour Time-Series Raw Data
Current Value: XX
Daily Average: XXX
X Week: XX -XX%
X Month: XXXXX -XX%
X Months: XXXXXX +40%
X Year: XXXXXX +53%
1-Year High: XXXXX on 2025-10-20
1-Year Low: X on 2024-12-20

Engagements by network (24h): X: XX

Mentions: X (24h)

Mentions 24-Hour Time-Series Raw Data
Current Value: X
Daily Average: X
X Week: X no change
X Month: X +100%
X Months: XX no change
X Year: XX +225%
1-Year High: X on 2024-12-15
1-Year Low: X on 2024-12-19

Mentions by network (24h): X: X

Creators: X (24h)

Creators 24-Hour Time-Series Raw Data
X unique social accounts have posts mentioning $rvmds in the last XX hours which is no change from in the previous XX hours Daily Average: X
X Week: X no change
X Month: X no change
X Months: X +14%
X Year: XX +180%
1-Year High: X on 2024-12-15
1-Year Low: X on 2024-12-18

Top $rvmds Social Posts

Top posts by engagements in the last XX hours

Showing only X posts for non-authenticated requests. Use your API key in requests for full results.

"Mizuho🏁 $RVMD Outperform/$90 $ZLAB AMGN BMY VSTM $IMRX Mizuho in its initiation report said: We see RVMD's portfolio of RAS(ON) inhibitors as positioned to play significant roles in PDAC NSCLC and CRC. Specifically we believe daraxonrasib in PDAC alone and additional near-term de-risking can drive meaningful upside. First we expect future 1L PDAC updates and insights into PFS/OS to mature favorably and drive greater conviction around the Phase III RASolute XXX study. Second scenario modeling of the Phase III RAsolute XXX trial in 2L PDAC points to a high probability of success and we believe"
X Link @Quantumup1 2025-10-20T20:19Z 3935 followers, 6919 engagements